Leveraging this NAA-induced suppression, the combination of STZ and NAA achieves two key objectives for T2DM modeling: downregulating PARP-1 activation to preserve residual β-cells and inhibiting SIRT1 to mimic insulin resistance. The gene discussed is PARP1; the disease is type 2 diabetes mellitus.